Sarepta Therapeutics' Elevidys for DMD shows revenue potential, with market cap justified at $11.4bn and potential for >50% ...

As the year unfolds the biotech industry will look closely at these ten first-in-class drugs on track to reach FDA approval ...

And while Wood said the pharma still isn’t interested in joining the overcrowded obesity landscape, GSK is considering ways ...

Biopharma executives were busy Monday, striking high-value deals and providing updates on cancer, obesity and vaccine ...

Sarepta Therapeutics’ Duchenne muscular dystrophy therapy Elevidys handily beat analysts’ expectations in the fourth quarter ...

Biotech stocks are poised for an exciting 2025 as experts watch for new weight-loss drugs, AI's impact and Trump's second ...

RBC Capital lowered the firm’s price target on Sarepta (SRPT) to $165 from $182 and keeps an Outperform rating on the shares as part of a ...

CEO Christopher Richard Anzalone sold 11,520 shares of the stock in a transaction that occurred on Thursday, January 2nd. The ...

B. Riley upped their FY2025 earnings per share estimates for shares of Arrowhead Pharmaceuticals in a report issued on ...

Arrowhead Pharmaceuticals Inc is a biotechnology company. It is engaged in the development of medicine to treat diseases such as hepatitis B, and thrombosis with a genetic origin, primarily divided by ...

Re­gen­eron, mak­er of the block­buster oph­thal­mol­o­gy med­i­cine Eylea, has ac­quired an oc­u­lar biotech, the large bio­phar­ma con­firmed to End­points News on Thurs­day.